Standout Papers

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open... 2018 2026 2020 2023 246
  1. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial (2018)
    Giuseppe Lombardi, Gian Luca De Salvo et al. The Lancet Oncology

Immediate Impact

60 standout
Sub-graph 1 of 23

Citing Papers

Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers
2024 Standout
The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology
2024 Standout
7 intermediate papers

Works of Luisa Bellu being referenced

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
2018 Standout
Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials
2017
and 1 more

Author Peers

Author Last Decade Papers Cites
Luisa Bellu 444 212 117 156 43 655
Ardi Pambuku 435 163 80 168 27 620
Ivan Lolli 377 192 72 151 40 645
Myra E. van Linde 355 151 106 213 34 690
Ugonma Chukwueke 353 254 127 214 47 752
Yong Cui 347 255 183 160 59 776
Marina Faedi 399 209 86 150 27 689
Nicole Shonka 525 223 193 265 43 837
Eric Burton 394 201 90 202 40 753
T. Mikkelsen 509 218 101 265 21 721
Haihui Jiang 492 157 210 131 55 660

All Works

Loading papers...

Rankless by CCL
2026